Method for treating breast cancer
US11084872B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Oct 18, 2018 |
| Grant date | Aug 10, 2021 |
| Priority date | — |
| Expiry date | Apr 21, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Breast cancer cells lacking ER protein expression, PgR protein expression and/or showing absence of HER2 protein over-expression (i.e., triple-negative breast cancer cells, basal-like) can be efficiently targeted with an anti-KAAG1 antibody and killed upon delivery of a therapeutic moiety. Antibodies and antigen binding fragments that specifically binds to KAAG1 may thus be used for the, detection and therapeutic treatment of breast cancer cells that are negative for at least one of these markers. The use of antibody conjugates in the treatment of triple-negative breast cancer and/or basal-like breast cancer is disclosed herein.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.